Dr. Parker on current role of FDA-approved PSMA-PET imaging agents in clinical practice

Video

Currently there are 2 FDA-approved, commercially available PSMA-PET imaging agents, which are Gallium 68 PSMA-11 (Ga 68 PSMA-11) and piflufolastat F 18 (Pylarify). In this video, William P. Parker, MD, discusses their approved indications and current role in the prostate cancer paradigm. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Dr. Daniel Spratt in an interview with Urology Times
Dr. Benjamin Lowentritt in an interview with Urology Times
Phillip H. Kuo, MD, PhD, FACR, answers a question during a Zoom video interview
blurred image of a clinic hallway
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.